Business Context and Reporting Period
This Form 10-Q was filed by Aastrom Biosciences, Inc., not Vericel Corp., for the quarter ended March 31, 2012. Aastrom was a development-stage regenerative medicine company focused on ixmyelocel-T, an autologous, expanded multicellular therapy for severe cardiovascular diseases, primarily critical limb ischemia (CLI) and dilated cardiomyopathy (DCM).
The company had no material commercial revenue and operated in one reportable segment. Its principal activities were research, clinical development, manufacturing preparation, and regulatory advancement.
Key Financial Metrics
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Total revenue | $2 thousand | $9 thousand |
| Research and development expense | $6.796 million | $4.372 million |
| Selling, general and administrative expense | $1.762 million | $1.895 million |
| Total costs and expenses | $8.560 million | $6.269 million |
| Loss from operations | $8.558 million | $6.260 million |
| Net loss attributable to common shareholders | $9.744 million | $4.988 million |
| Loss per share | $0.25 | $0.13 |
| Net cash used in operating activities | $6.603 million | $6.419 million |
- Cash and cash equivalents were $36.733 million at March 31, 2012, versus $5.530 million at December 31, 2011.
- The quarter-end cash increase of $31.203 million primarily reflected $37.723 million of net proceeds from the March 2012 issuance of Series B-1 convertible preferred stock.
- Total assets were $38.664 million; total liabilities were $22.376 million.
- Warrant liabilities increased from $16.625 million to $17.525 million, producing a $0.900 million non-cash expense in the quarter.
- Long-term debt was $29 thousand, with an additional $40 thousand classified as current debt.
- The filing does not provide a meaningful operating margin because revenue was immaterial and the company remained in the development stage.
- Accumulated deficit was $251.592 million at March 31, 2012.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased 55% to $6.796 million, primarily due to increased staffing and clinical activity. CLI-related spending increased to $6.109 million from $2.353 million, while DCM-related spending declined to $0.687 million from $1.997 million.
- Net loss attributable to common shareholders nearly doubled to $9.744 million, or $0.25 per share, from $4.988 million, or $0.13 per share.
- The prior-year quarter included $1.254 million of non-cash warrant fair-value income; Q1 2012 included a $0.900 million non-cash warrant fair-value expense. This change materially affected the year-over-year loss comparison.
- Cash flow from operations remained substantially negative, increasing modestly to $6.603 million used from $6.419 million used.
- On March 9, 2012, the company issued 12,308 shares of Series B-1 preferred stock for net proceeds of $37.723 million. The preferred stock carried cumulative, compounding dividends of 11.5% annually through the fifth anniversary, subject to the terms described in the filing.
- Research and development activity advanced into Phase 3 for CLI, while the company planned a Phase 2b DCM trial for mid-2012.
Guidance, Outlook, Risks, and Unusual Items
- Management expected existing cash to fund planned operations through at least December 31, 2012, based on current assumptions and spending plans.
- The company did not expect positive operating cash flow for at least several years and stated that substantial additional funding would be required to complete development, clinical trials, regulatory approvals, and commercialization.
- Potential cash conservation actions included delaying hiring, deferring non-critical research and development, and slowing certain clinical activity, although management stated it did not intend to jeopardize the Phase 3 CLI trial.
- The pivotal Phase 3 REVIVE trial was designed to enroll 594 no-option CLI patients at approximately 80 U.S. sites, with amputation-free survival as the primary efficacy endpoint. The filing states that screening began in February 2012; it also reports that the first patient was randomized and aspirated in May 2012, after the quarter-end.
- The company planned to initiate a randomized, placebo-controlled Phase 2b trial in up to 100 ischemic DCM patients in mid-2012.
- Clinical results to date were preliminary and not necessarily predictive of later trial outcomes. Key risks included clinical-trial failure, regulatory delays or rejection, manufacturing requirements, market acceptance, competition, and inability to raise additional capital.
- The Series B preferred stock was presented as mezzanine equity and was subject to accretion toward a stated redemption value. Subsequent to quarter-end, shareholder approval allowed the B-1 shares to exchange for B-2 voting preferred shares on May 3, 2012.
- Warrant liabilities used Level 3 valuation inputs and could create significant future non-cash income or expense without affecting cash flows.
- The company reported no material pending legal proceedings, no material changes to previously disclosed risk factors, and no off-balance-sheet arrangements.
Most Important Facts to Verify
- Confirm the issuer identity: the supplied filing is for Aastrom Biosciences, Inc., while the request identifies Vericel Corp.
- Verify the timing, enrollment, and subsequent results of the Phase 3 REVIVE CLI trial and the planned Phase 2b DCM trial.
- Assess whether the $36.733 million cash balance was sufficient beyond December 31, 2012 and when additional financing was required.
- Review the terms, accrued dividends, redemption provisions, and conversion mechanics of the Series B preferred stock.
- Monitor the effect of warrant-liability remeasurement and potential dilution from approximately 35.6 million excluded common-equivalent shares.
- Evaluate whether clinical efficacy and safety results were confirmed in larger, later-stage trials and whether FDA approval and commercialization were achieved.